Journal
EUROPEAN JOURNAL OF CANCER
Volume 42, Issue 16, Pages 2692-2705Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.06.022
Keywords
breast cancer; tamoxifen-resistance; predictive marker; AIB1; HER-2; oestrogen receptor; progesterone receptor; cox-2; cyclin E; UPA/PAI-1
Categories
Ask authors/readers for more resources
Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positive patients. Unfortunately, despite high ER tumour levels in a tumour, resistance to endocrine therapy, either de novo or acquired after prolonged treatment, can occur. In this review, we will try to summarise the postulated mechanisms of hormonal-resistance, namely, the role of co-regulators and the crosstalk between the HER-2, IGF-IR, Cox-2 and ER pathways. Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available